CV Sciences (CVSI) Income towards Parent Company (2011 - 2026)
CV Sciences' (CVSI) quarterly Income towards Parent Company came in at -$643000.0 in Q1 2026, down 489.91% year-on-year from $164910.6 in Q1 2025, and down 269.66% quarter-over-quarter from $379000.0 in Q4 2025.
CV Sciences (CVSI) Income towards Parent Company (2011 - 2026) Analysis & Trends
CV Sciences has disclosed Income towards Parent Company across 16 years of filings, most recently posting -$643000.0 for Q1 2026.
- Income towards Parent Company for Q1 2026 came in at -$643000.0, down 489.91% year-over-year; the trailing twelve-month figure through Mar 2026 was -$907000.0 (up 51.63% YoY), and the FY2025 annual result was -$373000.0, up 84.42% from the prior year.
- Income towards Parent Company came in at -$643000.0 for Q1 2026 at CV Sciences, down from $379000.0 in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $5.7 million in Q1 2023 to a low of -$4.0 million in Q4 2023.
- The 5-year median for Income towards Parent Company is -$628000.0 (2024), against an average of -$643176.5.
- Across the five-year window, Income towards Parent Company tumbled 2477.5% in 2022 and soared 476.63% in 2023, its largest moves.
- CV Sciences' Income towards Parent Company stood at -$2.3 million in 2022, then plunged by 72.2% to -$4.0 million in 2023, then jumped by 81.77% to -$726000.0 in 2024, then soared by 152.2% to $379000.0 in 2025, then slumped by 269.66% to -$643000.0 in 2026.
- The last three Income towards Parent Company figures came in at -$643000.0 (Q1 2026), $379000.0 (Q4 2025), and -$382000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn |
| 10 | CV Sciences | - | - | 1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -643,000.00 |
| Dec 31, 2025 | 379,000.00 |
| Sep 30, 2025 | -382,000.00 |
| Jun 30, 2025 | -261,000.00 |
| Mar 31, 2025 | -109,000.00 |
| Dec 31, 2024 | -726,000.00 |
| Sep 30, 2024 | -456,000.00 |
| Jun 30, 2024 | -584,000.00 |
| Mar 31, 2024 | -628,000.00 |
| Dec 31, 2023 | -3.98 Mn |
| Sep 30, 2023 | -447,000.00 |
| Jun 30, 2023 | -1.29 Mn |
| Mar 31, 2023 | 5.71 Mn |
| Dec 31, 2022 | -2.31 Mn |
| Sep 30, 2022 | -1.03 Mn |
| Jun 30, 2022 | -2.65 Mn |
| Mar 31, 2022 | -1.52 Mn |
| Dec 31, 2021 | -8.86 Mn |
| Sep 30, 2021 | -40,000.00 |
| Jun 30, 2021 | -3.53 Mn |